Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study

Table 2 Hazard ratios (HRs) for discontinuation of clopidogrel treatment

Time following DES implantation		HR (95% CI)	Adjusted HR (95% CI)
MACE	0-3 months	2.48 (1.30-4.71)	2.06 (1.08-3.93)
	3-6 months	1.26 (0.68-2.33)	1.29 (0.70-2.41)
	6-12 months	1.26 (0.53-2.99)	1.29 (0.54-3.07)
Cardiac death	0-3 months	6.84 (3.06-15.3)	4.80 (2.13-10.8)
	3-6 months	1.95 (0.72-5.30)	1.85 (0.68-5.04)
	6-12 months	1.65 (0.42-6.46)	1.74 (0.45-6.78)
Myocardial infarction	0-3 months	2.05 (0.93-4.53)	1.84 (0.83-4.09)
	3-6 months	1.08 (0.51-2.28)	1.14 (0.54-2.43)
	6-12 months	1.09 (0.36-3.35)	1.09 (0.35-3.34)
Definite stent thrombosis	0-3 months	-	-
	3-6 months	6.04 (0.52-70.2)	7.14 (0.61-83.7)
	6-12 months	-	-

MACE is a composite of cardiac death, myocardial infarction, and definite stent thrombosis.
Abbreviations: HR hazard ratio, CI confidence interval.
Hazard ratios were adjusted for age, gender, year of index PCI, PCI indication, comorbidity level (using Charlson Comorbidity Index scores), and time-varying use (calculated from the number of days exposed) of aspirin, other NSAIDs, and proton pump inhibitors.
0-3 months = day 1 through 91; 3 to 6 months = day 92 through 182; 6 to 12 months = day 183 through 365.

ISSN: 1471-2261